Why the study?
Coronary chronic total occlusion in an infarct-related artery (IRACTO) independently predicts ventricular arrhythmias, but whether IRACTO revascularization reduces arrhythmia burden is unknown.
Does revascularization of a coronary chronic total occlusion in an infarct-related artery reduce appropriate ICD therapies in patients with prior myocardial infarction and secondary prevention ICD?
Does revascularization of a coronary chronic total occlusion in an infarct-related artery reduce appropriate ICD therapies in patients with prior myocardial infarction and secondary prevention ICD?
Successful revascularization of an infarct-related artery chronic total occlusion in patients with prior MI and a secondary prevention ICD is associated with a significantly lower incidence of appropriate ICD therapies.
Answers are grounded in this paper and cite their sources.
IRA revascularization was associated with fewer ICD therapies; hypothesis-generating pending randomized confirmation.
OBJECTIVES: To evaluate whether the revascularization of a coronary chronic total occlusion in an infarct-related artery (IRACTO) may be associated with lower recurrence of ventricular arrhythmias (VA) among patients with a secondary prevention implantable cardioverter defibrillator (ICD). BACKGROUND: IRACTO is increasingly recognized as an independent predictor of VA. It is unknown whether IRACTO revascularization can reduce the burden of VA. METHODS: Multicenter observational cohort study that included consecutive patients with prior myocardial infarction and secondary prevention ICD. The primary endpoint was any appropriate ICD therapy. RESULTS: Among the 460 patients included, 269 (58%) had at least one IRACTO at the coronary angiogram performed before ICD implantation; of these, 20 (7%) had their IRACTO successfully revascularized (IRACTO-R) afterwards. During a median follow-up of 48 months, 229 patients (49%) had at least one appropriate ICD therapy. Patients with IRACTO not revascularized (IRACTO-NR) had the highest incidence of ICD therapies (65%) while patients with IRACTO-R had the lowest (10%, p < .001). In the entire cohort, IRACTO-NR was an independent predictor of appropriate ICD therapies (HR 2.85, p < .001) and appropriate ICD shocks (HR 2.94, p < .001). Among patients with IRACTO at baseline, IRACTO-R was independently associated with a marked reduction of appropriate ICD therapies (HR 0.12, p = .002) and appropriate ICD shocks (HR 0.21, p = .03). CONCLUSIONS: In patients with prior myocardial infarction and secondary prevention ICD, IRACTO revascularization was independently associated with a markedly lower incidence of appropriate ICD therapies and shocks. These results should be corroborated by larger prospective studies.
No takes yet. Share an insight, caveat, or question.
Marco et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: